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Objective: to determine the effect of specific antibiotic treatment with roxithromycin in the eradication of Chlamydia
pneumoniae from carotid artery plaques.
Design: prospective open randomised treatment study.
Patients and methods: we analysed 32 patients (16 females, mean age 70.1–14.7 years) who underwent surgery for
the removal of atherosclerotic plaques from carotid arteries. During surgery samples of lingual vein and superior thyroid
artery were also taken. Before surgery, patients were randomised to receive either roxithromycin 150 mg twice daily or
no treatment. Sixteen patients were treated with antibiotic for a mean of 26 days (range 17–35 days). The two groups of
patients were comparable in terms of age, sex, risk factors, and seroprevalence for C. pneumoniae. We applied a semi-
nested polymerase chain reaction (PCR) technique to the carotid plaques, lingual vein, and thyroid artery samples. Blood
samples were obtained from the patients for the determination of C. pneumoniae IgG, IgA, and IgM antibody titres by
a microimmunofluorescence technique.
Results: in twelve out of sixteen non-treated patients we found evidence of C. pneumoniae DNA in the carotid plaques.
Conversely, C. pneumoniae DNA was detected in only five out of sixteen treated patients (p=0.034, Chi-squared test).
In all cases PCR was negative for the lingual vein and thyroid artery samples.
Conclusions: Roxithromycin seems effective in reducing the bacterial burden of C. pneumoniae within atherosclerotic
plaques, although extended follow-up is needed to determine whether antibiotic treatment benefits long-term patient
outcome.
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Introduction spindle-cell lesions) in a rabbit model infected with
C. pneumoniae, and in a similar animal model
Muhlestein9 demonstrated that weekly treatmentDuring this decade chronic infection has emerged
with azithromycin after infectious exposure preventsas a putative causal factor in the development of
accelerated intimal thickening. An intervention trialatherosclerosis. Most studies have evaluated the as-
suggests that an increased anti-C. pneumoniae anti-sociation between current or previous infections with
body titre may be a predictor for further adversecytomegalovirus, Helicobacter pylori, and Chlamydia
cardiovascular events in male survivors of myocardialpneumoniae.1–6
infarction and that administration of a macrolideThe presence of C. pneumoniae in coronary and
leads to a reduction of the cardiovascular risk.10carotid artery plaques, and in abdominal aortic
A persistent infection may contribute to the de-aneurysms has been demonstrated by means of im-
velopment of atherosclerosis by stimulating local re-munocytochemical, molecular biology, culture, and
sponses, all the more so since C. pneumoniae is capableelectron microscope techniques.3–6
of inducing the endothelial production of tissueRecent studies7,8 reproduced early atherosclerotic
factors, which determine the stimulation of the co-arterial wall degeneration (fatty streaks and complex
agulation cascade and platelet adhesion and local
thrombosis.11 Furthermore, C. pneumoniae induces
* Please address all correspondence to: F. Blasi, Isituto di Tisiologia macrophage foam-cell formation.12 We recently dem-
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the hypothesis that C. pneumoniae infection may cause for 1 minute. DNA was amplified in 50-ll volumes
containing 50 lmol of dNTP, 0.5 lmol of each primerinstability within atherosclerotic plaques.13 Chiu et al.2
found that atherosclerotic plaques with thrombosis (HL-1 and HR-1), 1 unit Taq polymerase, 5 mmol
MgCl2, 1 mmol Tris HCl, 50 mmol KCl pH 8.3. Thewere more likely to have C. pneumoniae than plaques
without thrombosis. second PCR reaction was performed starting with
2 ll of the first amplificate as follows: samples wereThe aim of the present study was to determine
whether specific antibiotic treatment was capable of pretreated at 94 °C for 5 minutes, and amplified for
35 cycles. Each cycle consisted of the following: de-eradicating C. pneumoniae from carotid plaques.
naturation at 94 °C for 1 minute, annealing at 48 °C
for 1 minute and primer extension at 72 °C for 1 min-
ute. DNA was amplified in 50-ll volumes containing
Subjects and Methods 200 lmol of dNTP, 0.5 lmol of each primer (HR-1 and
HM-1), 1 unit Taq polymerase, 3 mmol MgCl2, 1 mmol
Between November 1997 and April 1998 we analysed Tris-HCl, 50 mmol KCl pH 8.3. The amplifications
32 patients (16 females, mean age 70.1–14.7 years) were performed in an automated thermocycler (Robo-
who underwent carotid endarterectomy (CEA). All cycler, Stratagene, U.S.A.). The presence of Taq-
patients gave their informed consent prior to en- polymerase inhibitors in the specimens was tested.
rolment. Patients were randomised to receive before In a single test-tube, 10 ll of biopsy-extracted DNA
surgery either roxithromycin 150 mg twice daily or and 10 ll of DNA extracted from the positive control
no treatment. Sixteen patients were treated with anti- were denatured by heat (94 °C for 3 minutes) and
biotic for a mean of 26 days (range 17–35 days). The then in ice. Next, 10 ll were drawn to be added to
two groups of patients were comparable in terms the 40 ll mixtrure for the first amplification of the
of age, sex, risk factors and seroprevalence for C. PCR. The first amplification was then run, followed
pneumoniae. During surgery, samples of carotid by the second step in accordance with the study
plaques, lingual vein and a superior thyroid artery protocol.
branch were taken. The amplification reaction was tested by means of
We applied a polymerase chain reaction (PCR) for gel electrophoresis by running 10 ll of amplificate on
the detection of bacterial DNA to the carotid plaques, a 3% agarose gel. The absence of an amplification
lingual vein, and superior thyroid artery specimens. band indicates the presence of inhibitors in the speci-
DNA was isolated by homogenisation using TriPureÔ men. At admission, on the day of surgery, and after 4
Isolation Reagent (Boehringer Mannheim, Germany) weeks, blood samples were obtained from the patients
according to the manufacturer’s instructions. Briefly, for the determination of C. pneumoniae IgG, IgA, and
for each 50 mg of tissue 1 ml of TriPure Isolation IgM antibody titres by a microimmunofluorescence
Reagent was added to a propylene centrifuge tube at test13 using a kit purchased from Labsystems,
room temperature. After homogenisation 0.2 ml of Helsinki, Finland.
chloroform (for each 1 ml of TriPure reagent) was
added. After shaking vigorously for 15 seconds, the
sample tube was left at room temperature for 10
minutes and then centrifuged at 12.000 g for 15 min- Results
utes at 4 °C.
DNA was retrieved by ethanol extraction from both In the treated group 12/16 patients were seropositive
for C. pneumoniae on admission, and 9/16 were sero-the interphase and the red organic phase obtained
after the centrifugation described above. Following positive in the non-treated group (p=0.45, Chi-
squared test). In 12/16 non-treated patients we foundeach extraction the presence of genetic material was
detected by means of spectrophotometry. evidence of C. pneumoniae DNA in the carotid plaques.
Conversely, C. pneumoniae DNA was detected in onlyWe applied a PCR using two sets of primers de-
scribed by Campbell:15 HL-1, GTTGTTCATGAA- 5/16 treated patients (p=0.034, Chi-squared test). No
evidence of C. pneumoniae DNA was found in any ofGGCCTACT; HM-1, GTGTCATTCGCCAAGGTTAA;
and HR-1, TGCATAACCTACGGTGTGTT. The first the lingual vein and thyroid artery samples.
Among the 12 non-treated patients with presence ofPCR reaction was modified as follows: samples were
pretreated at 94 °C for 5 minutes, and amplified for C. pneumoniae DNA, serology results were consistent
with chronic infection in 8/12 cases, negative in35 cycles. Each cycle consisted of the following:
denaturation at 94 °C for 1 minute, annealing at 3/12, and the serum samples were missing in 1/12
patients. Out of the four non-treated patients with55 °C for 1 minute and primer extension at 72 °C
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Table 1. Clinical characteristics, serology on admission and molecular biology findings in the 16 treated patients.
Pt Sex Age Risk factors and concomitant diseases Serology on admission C. pneumoniae DNA
IgG IgA IgM
1 F 54 Hypertension, diabetes, dyslipidaemia <1:16 <1:16 <1:16 Positive
2 F 64 Dyslipidaemia 1:256 <1:16 <1:16 Negative
3 M 64 Smoking, hypertension, dyslipidaemia, CHD <1:16 <1:16 <1:16 Negative
4 F 67 Smoking, hypertension, dyslipidaemia <1:16 <1:16 <1:16 Negative
5 M 68 Smoking, hypertension, dyslipidaemia, CHD, stroke 1:512 <1:16 <1:16 Negative
6 M 73 Smoking, hypertension, dyslipidaemia 1:256 <1:16 <1:16 Negative
7 M 76 COPD, smoking, hypertension 1:64 <1:16 <1:16 Negative
8 F 77 CHD, obesity 1:256 <1:16 <1:16 Positive
9 F 77 Hypertension, dyslipidaemia <1:16 <1:16 <1:16 Negative
10 F 77 Hypertension, dyslipidaemia 1:64 1:32 <1:16 Positive
11 F 81 Hypertension, CHD 1:512 <1:16 <1:16 Positive
12 M 82 Smoking, CHD, obesity, stroke 1:64 1:128 <1:16 Negative
13 M 82 Smoking, hypertension, stroke 1:64 <1:16 <1:16 Negative
14 F 82 Hypertension 1:256 <1:16 <1:16 Negative
15 F 83 Hypertension, dyslipidaemia, stroke 1:64 <1:16 <1:16 Negative
16 F 86 COPD, dyslipidaemia, obesity 1:64 1:32 <1:16 Positive
Pt=Patient; COPD=chronic obstructive pulmonary disease; CHD=coronary heart disease.
Table 2. Clinical characteristics, serology on admission and molecular biology findings in the 16 non-treated patients.
Pt Sex Age Risk factors and concomitant diseases Serology on admission C. pneumoniae DNA
IgG IgA IgM
1 F 42 COPD, hypertension, diabetes 1:128 <1:16 <1:16 Positive
2 M 62 Smoking, hypertension, CHD 1:256 <1:16 <1:16 Positive
3 F 62 Hypertension, dyslipidaemia, obesity <1:16 <1:16 <1:16 Positive
4 F 66 Hypertension, stroke <1:16 <1:16 <1:16 Positive
5 F 70 Smoking, stroke 1:128 <1:16 <1:16 Positive
6 M 70 COPD, CHD, obesity, stroke 1:64 1:32 <1:16 Positive
7 M 70 Hypertension, CHD 1:64 <1:16 <1:16 Positive
8 M 71 Hypertension, dyslipidaemia <1:16 <1:16 <1:16 Negative
9 F 73 Smoking, hypertension <1:16 <1:16 <1:16 Positive
10 M 73 COPD, smoking, CHD <1:16 <1:16 <1:16 Negative
11 F 74 Smoking, hypertension, dyslipidaemia 1:16 1:32 <1:16 Positive
12 M 74 Dyslipidaemia, hypertension NA NA NA Positive
13 M 77 Hypertension, obesity 1:256 1:64 <1:16 Positive
14 F 77 Hypertension, CHD, stroke 1:64 <1:16 <1:16 Positive
15 F 78 Hypertension, dyslipidaemia 1:64 <1:16 <1:16 Negative
16 M 82 Smoking, hypertension, stroke <1:16 <1:16 <1:16 Negative
Pt=Patient; NA=not available; COPD=chronic obstructive pulmonary disease; CHD=coronary heart disease.
no evidence of C. pneumoniae genetic material, sero- 4 weeks following surgery). In all cases PCR was
negative on lingual vein or thyroid artery samples.logy was negative in three cases and positive in one
case. In the five treated patients with PCR positivity Table 1 and Table 2 summarises clinical char-
acteristics, serology at admission, and molecular bio-for C. pneumoniae, pre-treatment serology results were
consistent with chronic infection in four cases, neg- logy results of treated and non-treated patients,
respectively.ative in one case. Among the 11 treated patients
for whom C. pneumoniae was not detected by PCR, PCR was repeated twice on each specimen. In 29/
32 cases both PCR test results were unequivocal.serology on admission was negative in three cases
and positive in eight cases. When the test results were not unequivocal we con-
sidered the sample to be negative. There was noNo significant variations in antibody titres were
recorded in the two groups over the entire study evidence of Taq-polymerase inhibitors in the biopsy
samples. We tested for a possible correlation betweenperiod (on admission, on the day of surgery, and at
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C. pneumoniae positivity (as determined both by sero- the limit of detection of the PCR technique (10–100
elementary bodies), roxithromycin appears capablelogy and PCR) and a more severe form of arterial
stenosis (>70%). In terms of serology, the difference of penetrating within plaque lesions and acting on
the micro-organism.in number of severe forms of stenosis between C.
pneumoniae-positive (9/21) and C. pneumoniae-neg- In summary, the results of our study indicate that
roxithromycin is effective in reducing the bacterialative (2/10) patients was not statistically significant
(p=0.4). Conversely, in terms of PCR results, among burden of Chlamydia pneumoniae within athero-
sclerotic plaques, although extended follow-up isthe non-treated patients a more severe form of sten-
osis was observed in C. pneumoniae-DNA-positive needed to determine whether antibiotic treatment
benefits long-term patient outcome.patients (11/12) compared to C. pneumoniae-DNA-
negative (1/4) subjects (p=0.046, Chi-squared test).
We excluded the treated group from the analysis,
since the determination of PCR positivity was per-
formed following antibiotic treatment. Acknowledgement
Funding: This study was partially supported by IRCCS Ospedale
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